Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06806982




Registration number
NCT06806982
Ethics application status
Date submitted
6/01/2025
Date registered
4/02/2025

Titles & IDs
Public title
A Phase 1 Study of VRN101099 in Patients With HER2-Positive Solid Tumors
Scientific title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of VRN101099 in Patients With HER2-Positive Solid Tumors
Secondary ID [1] 0 0
VRN101099_01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
HER2-positive Solid Tumors 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - VRN101099

Experimental: VRN101099 - VRN101099 capsules will be administered orally as monotherapy once daily over 21-day cycles Dose and frequency of dosing: The planned doses for dose escalation are 80 mg, 160 mg, 240 mg, 320 mg, 400 mg, and 480 mg once daily.

Dosage form- Oral capsules


Treatment: Drugs: VRN101099
Oral capsules
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Estimate of Maximum tolerated dose (MTD) of VRN101099
Timepoint [1] 0 0
Up to 2 years post first dose administration
Primary outcome [2] 0 0
Number of participants with Adverse events (AEs) and Serious Adverse events (SAE) as assessed by Medical Dictionary for Regulatory Activities (MedDRA®).
Timepoint [2] 0 0
Up to 2 years post first dose administration
Primary outcome [3] 0 0
Number of patients with changes in ECOG performance status from baseline following treatment with VRN101099
Timepoint [3] 0 0
From Screening to 14 days post last dose
Primary outcome [4] 0 0
Number of patients with changes in physical/ophthalmic examination from baseline following treatment with VRN101099
Timepoint [4] 0 0
From Screening to 14 days post last dose
Primary outcome [5] 0 0
Number of patients with changes in laboratory tests from baseline following treatment with VRN101099
Timepoint [5] 0 0
From Screening to 14 days post last dose
Secondary outcome [1] 0 0
Plasma PK of VRN101099 and Cycle1 Day 1- Cmax
Timepoint [1] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [2] 0 0
Plasma PK of VRN101099 and Cycle1 Day 1-AUC0-last
Timepoint [2] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [3] 0 0
Plasma PK of VRN101099 and Cycle1 Day 1-AUC0-Inf
Timepoint [3] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [4] 0 0
Plasma PK of VRN101099 and Cycle1 Day 1-Tmax
Timepoint [4] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [5] 0 0
Plasma PK of VRN101099 and Cycle1 Day 1- ?z
Timepoint [5] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [6] 0 0
Plasma PK of VRN101099 and Cycle1 Day 1- t1/2
Timepoint [6] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [7] 0 0
Plasma PK of VRN101099 and Cycle1 Day 1- CL/F
Timepoint [7] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [8] 0 0
Plasma PK of VRN101099 and Cycle1 Day 15- Cmax,ss
Timepoint [8] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [9] 0 0
Plasma PK of VRN101099 and Cycle1 Day 15- Cmin,ss
Timepoint [9] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [10] 0 0
Plasma PK of VRN101099 and Cycle1 Day 15- Tmax,ss
Timepoint [10] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [11] 0 0
Plasma PK of VRN101099 and Cycle1 Day 15- AUC 0-last
Timepoint [11] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [12] 0 0
Plasma PK of VRN101099 and Cycle1 Day 15- swing
Timepoint [12] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [13] 0 0
Plasma PK of VRN101099 and Cycle1 Day 15- Fluctuation
Timepoint [13] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [14] 0 0
Plasma PK of VRN101099 and Cycle1 Day 15- Ctrough
Timepoint [14] 0 0
Blood sampling from pre dose to 24 hours post dose administration on Cycle1 Day 1 and Day 15 (C1D1, C1D15) and pre dose on Cycle 1 Day 8 (C1D8). Each Cycle-28 days. Additionally, on Predose on Cycle 2 Day 1, Cycle 2 Day 8 and Day 1 of subsequent cycles.
Secondary outcome [15] 0 0
To evaluate objective response rate (ORR)
Timepoint [15] 0 0
Up to 2 years post first dose administration
Secondary outcome [16] 0 0
Number of patients with disease Control Rate (DCR)
Timepoint [16] 0 0
Up to 2 years post first dose administration
Secondary outcome [17] 0 0
Number of patients with changes in duration of objective response (DOR)
Timepoint [17] 0 0
Up to 2 years post first dose administration
Secondary outcome [18] 0 0
To assess progression-free survival (PFS)
Timepoint [18] 0 0
Up to 2 years post first dose administration
Secondary outcome [19] 0 0
To assess time to progression (TTP)
Timepoint [19] 0 0
Up to 2 years post first dose administration

Eligibility
Key inclusion criteria
1. Aged = 18 years (patients in Korea must be aged = 19 years).
2. Able to comprehend and willing to sign an informed consent form and to abide by the study requirements and restrictions.
3. Has at least 1 evaluable lesion (measurable or non-measurable) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (note: metastatic brain lesions will also be assessed using the Response Assessment in Neuro-Oncology - Brain Metastases [RANO-BM] as an exploratory objective).
4. Has confirmed HER2-positive or mutated cancer as determined by immunohistochemistry (IHC) staining (IHC 1+, 2+, 3+) or next-generation sequencing (NGS) of tissue or circulating tumor DNA (i.e., evaluation of HER2 copy numbers or mutations) (note: documentation of HER2 status is required prior to Screening;
5. In the opinion of the Investigator, is medically confirmed to derive no clinical benefit from other standard therapies.
6. In the opinion of the Investigator, has a life expectancy > 6 months.
7. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at Screening.
8. Women of childbearing potential (WOCBP) who engage in heterosexual intercourse must agree to maintain effective contraception during the study and for up to 6 months after EOT; males whose sexual partners are WOCBP must also agree to maintain effective contraceptive method and should refrain from donating sperm during the study and for up to 6 months after EOT.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Has a confirmed HER2 exon 20 mutation (in the documented NGS test result).
2. Received any IP, cytotoxic chemotherapy, or other anticancer drugs from a previous treatment regimen or clinical study within 3 weeks of the first dose of the study IP (note: Rescreening will be permitted after a washout period of 3 weeks).
3. Has been previously treated with systemic anticancer treatment of more than 6 regimens for breast cancer or 3 regimens for other solid tumors (note: local administration of rituximab is allowed but intrathecal methotrexate or concurrent chemoradiotherapy is regarded as systemic therapy).
4. Has any AEs from previous chemotherapy that have not recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade = 1 (note: Grade = 2 peripheral neuropathy or hair loss is acceptable).
5. Is a female who is pregnant, breastfeeding, or (among those of childbearing potential) planning to become pregnant.
6. Has a history of other active malignancy within 3 years prior to Screening (note: patients with non-melanoma skin cancer, in situ melanoma, or in situ cervical cancer are permitted to be enrolled).
7. Has any of the following laboratory abnormalities during Screening:

* Hematology (note: transfusion or hematopoietic growth factor administration within 14 days prior to Screening test is not allowed):

* -White blood cell (WBC) count < 2.5 × 10 power 9/L
* -Absolute neutrophil count (ANC) < 1500/µL
* -Platelets < 100000/µL
* -Hemoglobin < 9.0 g/dL.
* Clinical chemistry:

* -Creatinine clearance < 60 mL/min according to the Cockroft-Gault equation
* -Total bilirubin > 1.5 × ULN
* -Aspartate aminotransferase/transaminase (AST or SGOT) > 2.5 × ULN (> 5 × ULN with liver metastases)
* - Alanine aminotransferase/transaminase (ALT or SGPT) > 2.5 × ULN (> 5 × ULN with liver metastases).
8. Currently has uncontrolled NCI-CTCAE Grade = 2 hypercalcemia.
9. Has undergone prior treatment with a cumulative dose of doxorubicin of > 360 mg/meter square or previous treatment with another anthracycline with a cumulative dose equivalent to > 360 mg/meter square doxorubicin.
10. Has a current infection (including tuberculosis infection, among others) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days prior to the first dose of the IP (note: antiviral therapy is permitted for patients with hepatocellular carcinoma or chronic hepatitis B virus [HBV] or hepatitis C virus [HCV] infection).
11. Has untreated chronic hepatitis B or is a chronic HBV carrier (undetectable HBV DNA) at Screening (note: patients who are inactive hepatitis B surface antigen [HBsAg] carriers or have treated and stable hepatitis B (undetectable HBV DNA) can be enrolled; patients with detectable HBsAg or detectable HBV DNA should be managed per treatment guidelines. Patients receiving antivirals at Screening should have been treated for > 2 weeks before the first dose of IP).
12. Has active or chronic hepatitis C (note: patients with a negative HCV antibody test at Screening or positive HCV antibody test followed by a negative HCV RNA test at Screening are eligible; the HCV RNA test will only be performed for patients testing positive for HCV antibody. Patients receiving antivirals at Screening should have been treated for > 2 weeks before the first dose of IP).
13. Has a known history of human immunodeficiency virus infection.
14. Has received live vaccines within 4 weeks of the first dose of IP (note: the seasonal flu vaccines that does not contain live virus and coronavirus disease 2019 [COVID-19] vaccines are allowed).
15. Has had major surgery within 4 weeks prior to the first dose of the IP. Patients should have recovered from the effects of major surgery or significant traumatic injury within 16 days prior to the first dose of the IP (note: major surgery is defined as one that cannot be performed with local anesthesia [i.e., general anesthesia, respiratory assistance, or regional anesthesia] or an open biopsy).
16. Has received radiotherapy to a large field or including a vital organ within 14 days prior to the first dose of the IP (or 7 days prior to the first dose of the IP if a vital organ is not included).
17. Has central nervous system (CNS) metastases or spinal cord compression that are associated with progressive neurological symptoms, or that require treatment with more than 10 mg daily of prednisone or equivalent doses of corticosteroids, or that have not been on stable steroid treatment for at least 2 weeks prior to first drug administration (note: CNS metastases that have been either previously treated and controlled, or are symptomatic, or are untreated and asymptomatic are permitted and, when evaluable, should be captured as target lesion).
18. Has any other medical condition (with the exclusion of brain metastases as described above) requiring prednisone therapy of more than 10 mg daily or equivalent systemic steroid therapy (steroid replacement therapy for adrenal or pituitary insufficiency is permitted) or has received treatment with steroids for current or past non-infectious pneumonitis/interstitial lung disease.
19. Has impaired cardiac function or clinically significant cardiac disease, including:

* New York Heart Association Grade 2 or higher congestive heart failure.
* Left ventricular ejection fraction < 50% within the last 6 months.
* Coronary artery bypass graft or vascular stent implantation.
* Any other uncontrolled cardiac condition such as unstable angina, arrhythmias requiring treatment, atrial fibrillation, or hypertension (systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg).
* Baseline prolongation of QT interval corrected for heart rate using Fridericia's method (QTcF) of > 470 msec for females or > 450 msec for males determined (by the average of 3 readings on triplicate 12-lead ECG) or history of long QTc syndrome (congenital or otherwise) or Torsade de Pointes.
20. Is unable to swallow capsules or has intractable nausea, vomiting, or gastrointestinal diseases that interfere with proper absorption, or has any absorption disorders that may interfere with absorption of the IP.
21. Has known or suspected allergy or anaphylaxis to any component of the IP.
22. Has pleural effusion, ascites, or pericardial effusion requiring catheter drainage, peritoneal shunting, or Cell-free and concentrated Ascites Reinfusion Therapy (CART) (note: CART is not allowed within 2 weeks of the Screening visit).
23. Has retinal vascular disorder, retinopathy, glaucoma, or retinal detachment.
24. Any other clinically significant comorbidities, such as neurological or psychological disorders, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the subject to safety risks.
25. For any other reason, as determined by the Investigator, the patient is deemed inappropriate to participate in the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
11/02/2025
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/07/2027
Actual
Sample size
Target
72
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
St Vincent's Hospital Sydney - Darlinghurst
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Voronoi, Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Daekwon Kim
Address 0 0
Voronoi, Inc. Chief Executive Officer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Rutu Dabhi
Address 0 0
Country 0 0
Phone 0 0
+1 201-515-9340
Fax 0 0
Email 0 0
dabhirutu@voronoi.io
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06806982